Mortality Benefit of Recombinant Human Interleukin-1 Receptor Antagonist for Sepsis Varies by Initial Interleukin-1 Receptor Antagonist Plasma Concentration*
Nuala J. Meyer(Translational Therapeutics (United States)), Steven M. Opal(Brown University), Tiffanie K. Jones(Translational Therapeutics (United States)), Jessica A. Palakshappa(University of Pennsylvania), Jason D. Christie(University of Pennsylvania), Rui Feng(University of Pennsylvania), John P. Reilly(University of Pennsylvania), M.G.S. Shashaty(University of Pennsylvania), Thomas Dunn(Translational Therapeutics (United States)), Brian J. Anderson(University of Pennsylvania)
Cited by 98
Related Papers
The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3)
|JAMA|2016|28.1k
Surviving Sepsis Campaign
|Critical Care Medicine|2013|9.7k
Surviving Sepsis Campaign: International Guidelines for Management of Severe Sepsis and Septic Shock, 2012
|Intensive Care Medicine|2013|7.3k
2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference
|Critical Care Medicine|2003|6k
2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference
|Intensive Care Medicine|2003|2.9k